Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure

Yoshimi, Ayami; Baldomero, Helen; Horowitz, Mary M.; Szer, Jeff; Niederwieser, Dietger; Gratwohl, Aloïs; Kodera, Yoshihisa

doi:10.1001/jama.2015.13706

Cited by 21 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the haematopoietic stem cell transplantations use PBSC . However, BM harvest is still an important HSC source for transplantation in certain medical scenarios, such as bone marrow failure or haematopoietic stem cell transplantation in children . Marrow can also be used with success in haploidentical transplantation, and with increase in this type of the procedures, we can expect increase in bone marrow harvests (BMH) in related donors.…”

Section: Introductionmentioning

confidence: 99%

Bone marrow harvest in donors with anaemia

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Bone marrow harvest in donors with anaemia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Third, the number of cases using PB as a stem cell source overtook those using BM, even for non-malignant diseases (Table 3 ). This trend is largely attributable to India and differs from the patterns observed in the US and Europe [ 30 ]. In India, PBSCT is preferentially selected to improve engraftment in patients with non-malignant diseases under non-radiation regimens (from a personal communication with A Srivastava).…”

Section: Discussionmentioning

confidence: 79%

Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005–2015

Iida

Kodera

Dodds

et al. 2019

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Between 2005 and 2015, 138,165 hematopoietic stem cell transplantation (HSCT) were reported in 18 countries/regions in the Asia-Pacific region. In this report, we describe current trends in HSCT throughout the Asia-Pacific region and differences among nations in this region and various global registries. Since 2008, more than 10,000 HSCTs have been recorded each year by the Asia-Pacific Blood and Marrow Transplantation Group Data Center. Between 2005 and 2015, the greatest increase in the number of HSCTs was observed in Vietnam. Allogeneic HSCT was performed more frequently than autologous HSCT, and a majority of cases involved related donors. Regarding allogeneic HSCT, the use of cord blood has remained steady, especially in Japan, and the number of cases involving related HLA non-identical donors has increased rapidly, particularly in China. The incidence of hemoglobinopathy, a main indication for allogeneic HSCT in India, China, Iran, and Pakistan, increased nearly six-fold over the last decade. Among the 18 participating countries/regions, the transplant rate per population varied widely according to the absolute number of HSCTs and the national/regional population size. We believe that this report will not only benefit the AP region but will also provide information about HSCT to other regions worldwide.

show abstract

“…bone marrow and hence, its use will be limited to paediatrics and PBSC grafts. The utilization of PBSC grafts is increasing though because of ease of collection; hence this grafting technique holds the potential to become applicable globally 30 , 31 .…”

Section: Discussionmentioning

confidence: 99%

The role of graft T-cell size in patients receiving alemtuzumab serotherapy for non-malignant disorders: results of an institutional protocol

Pandrowala,

Khan,

Kataria

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Although graft T cells assist in engraftment, mediate antiviral immune-reconstitution, and cause graft-versus-host disease, graft size is not determined by T-cell content of the graft. The conventional method of graft size determination based on CD34+ cells with alemtuzumab serotherapy is associated with delayed immune reconstitution, contributing to an increased risk of viral infections and graft failure. Alemtuzumab, a long half-life anti-CD52 monoclonal antibody is a robust T-cell depleting serotherapy, and relatively spares memory-effector T cells compared to naïve T cells. We therefore hypothesized that graft size based on T-cell content in patients receiving peripheral blood stem cell graft with alemtuzumab serotherapy would facilitate immune-reconstitution without increasing the risk of graft-versus-host disease. We retrospectively analysed twenty-six consecutive patients with non-malignant disorders grafted using alemtuzumab serotherapy and capping of graft T cells to a maximum of 600 million/kg. The graft T-cell capping protocol resulted in early immune-reconstitution without increasing the risk of severe graft-versus-host disease. Graft T-cell content correlated with CD4+ T-cell reconstitution and acute graft-versus-host disease. The course of CMV viraemia was predictable without recurrence and associated with early T-cell recovery. No patient developed chronic graft-versus-host disease. Overall survival at one year was 100% and disease-free survival was 96% at a median of 899 days (range: 243–1562). Graft size determined by peripheral blood stem cell graft T-cell content in patients receiving alemtuzumab serotherapy for non-malignant disorders is safe and leads to early T-cell immune-reconstitution with excellent survival outcomes.

show abstract

Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure

Cited by 21 publications

References 5 publications

Bone marrow harvest in donors with anaemia

Bone marrow harvest in donors with anaemia

Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005–2015

The role of graft T-cell size in patients receiving alemtuzumab serotherapy for non-malignant disorders: results of an institutional protocol

Contact Info

Product

Resources

About